Paroxetine
Esophageal Neoplasms
Cancer Trials IrelandSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Esophageal Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LENVATINIB Merck Sharp & Dohme LLC | Phase 2 | B |
SIMUROSERTIB Millennium Pharmaceuticals, Inc. | Phase 2 | B |
Pembrolizumab/Vibostolimab Coformulation Merck Sharp & Dohme LLC | Phase 2 | B |
Mtc-Dox For FeRx | Phase 1/2 | CCC |
HX4 Maastricht Radiation Oncology | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
Paroxetine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →